Barclays Keeps Their Buy Rating on Vir Biotechnology (VIR)
at www.tipranks.com (Wed, 4-Feb 4:16 AM)
Vir Biotechnology’s Phase 2 Data Show 66% of CHD Patients Achieve Undetectable HDV RNA with Tobevibart and Elebsiran
Market Chameleon (Mon, 10-Nov 8:41 AM)
